MCAD Antibody (E-8): sc-271931

MCAD Antibody (E-8) is a mouse monoclonal IgM antibody that detects MCAD protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-MCAD antibody (E-8) is available as the non-conjugated form. Medium-chain acyl-CoA dehydrogenase (MCAD) plays a crucial role in the mitochondrial fatty acid β-oxidation pathway, catalyzing the initial step in the breakdown of medium-chain fatty acids, specifically those with acyl chain lengths ranging from 4 to 16 carbons. This enzymatic function is vital for energy production, particularly during periods of fasting when the body relies on fatty acids as an energy source. Deficiencies in MCAD can lead to serious metabolic disorders, including fasting hypoglycemia, hepatic dysfunction, and encephalopathy, which can be life-threatening, especially in infants. MCAD (E-8) antibody effectively detects a homotetramer composed of 421 amino acids featuring mitochondrial protein transit peptides, demonstrating 88% sequence identity with the porcine MCAD. Anti-MCAD antibody (E-8) serves as an essential tool for researchers studying metabolic pathways and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MCAD Antibody (E-8) References:

1. The Y42H mutation in medium-chain acyl-CoA dehydrogenase, which is prevalent in babies identified by MS/MS-based newborn screening, is temperature sensitive.  |  O'Reilly, L., et al. 2004. Eur J Biochem. 271: 4053-63. PMID: 15479234
2. Pulmonary haemorrhage and cardiac dysfunction in a neonate with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.  |  Maclean, K., et al. 2005. Acta Paediatr. 94: 114-6. PMID: 15858970
3. The difference between observed and expected prevalence of MCAD deficiency in The Netherlands: a genetic epidemiological study.  |  Derks, TG., et al. 2005. Eur J Hum Genet. 13: 947-52. PMID: 15870827
4. L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: a pilot study.  |  Lee, PJ., et al. 2005. J Inherit Metab Dis. 28: 141-52. PMID: 15877203
5. Newborns with C8-acylcarnitine level over the 90th centile have an increased frequency of the common MCAD 985A>G mutation.  |  Blois, B., et al. 2005. J Inherit Metab Dis. 28: 551-6. PMID: 15902558
6. Genotypic differences of MCAD deficiency in the Asian population: novel genotype and clinical symptoms preceding newborn screening notification.  |  Ensenauer, R., et al. 2005. Genet Med. 7: 339-43. PMID: 15915086
7. Down-regulation of Hsp60 expression by RNAi impairs folding of medium-chain acyl-CoA dehydrogenase wild-type and disease-associated proteins.  |  Corydon, TJ., et al. 2005. Mol Genet Metab. 85: 260-70. PMID: 15927499
8. Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA and its expression in enzyme-deficient human tissue.  |  Kelly, DP., et al. 1987. Proc Natl Acad Sci U S A. 84: 4068-72. PMID: 3035565
9. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.  |  Pugliese, M., et al. 2020. Orphanet J Rare Dis. 15: 12. PMID: 31937333
10. Molecular cloning of cDNAs encoding rat and human medium-chain acyl-CoA dehydrogenase and assignment of the gene to human chromosome 1.  |  Matsubara, Y., et al. 1986. Proc Natl Acad Sci U S A. 83: 6543-7. PMID: 3462713
11. Host-microbe co-metabolism via MCAD generates circulating metabolites including hippuric acid.  |  Pruss, KM., et al. 2023. Nat Commun. 14: 512. PMID: 36720857
12. A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.  |  Weeks, KL., et al. 2024. J Mol Med (Berl). 102: 95-111. PMID: 37987775

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MCAD Antibody (E-8) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-MCAD Antibody (E-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MCAD Antibody (E-8) Specifications

Alternate Product Name: MCAD

Product Clone Name: E-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 51-77

Epitope Target: MCAD

Epitope Species: human

Product Reactivity/Detection: MCAD

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for MCAD Antibody (E-8): P: Blocking Peptide